ArticleFrontiers in oncology2026
Sequential immune-related nephritis and pneumonitis during immune checkpoint inhibitor therapy: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have significantly improved cancer treatment but can cause immune-related adverse events (irAEs) that affect multiple organs and may develop over time. We present a case of sequential immune-related nephritis and pneumonitis during ICI therapy. The patient experienced severe acute kidney injury with a considerable increase in serum creatinine level, indicating immune-related nephritis. High-dose corticosteroids led to rapid recovery of kidney function, followed by a gradual taper. However, as the steroid dose was reduced, the patient developed fever and respiratory symptoms, with chest computed tomography revealing signs of immune-related pneumonitis. Prompt re-escalation of corticosteroids resulted in rapid improvement, allowing the taper to be continued slowly. This case highlights the dynamic, sequential nature of irAEs and emphasizes that new immune-mediated toxicities can emerge during steroid tapering even after initial irAE resolution. Therefore, close monitoring and timely therapy adjustments are essential for managing complex irAEs effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.